[Cyclosporin A in atopic dermatitis: therapeutic effect and effect on allergic reactions are dissociated from each other].

Wien Med Wochenschr

Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.

Published: March 1992

Fourteen patients with severe chronic atopic dermatitis were treated with cyclosporin A (CyA, Sandimmun; 5 mg/kg/day) for 7-16 weeks. All showed a marked clinical improvement and half could omit topical corticosteroid treatment during therapy. Adverse effects were minor, but two patients relapsed despite continued treatment. In the others, the disease recurred soon after stopping CyA. Serum IgE levels and prick-test responses were unchanged by CyA. Immediate and late-phase cutaneous responses to intradermal house dust mite antigen (HDM) were significantly increased during treatment; but a delayed response, present at 24 and 48 h, was unaffected. Four of six patients challenged with HDM patch tests to tape-stripped skin during treatment showed eczematous reactions at 48 h. Thus, cyclosporin A has a powerful therapeutic effect in atopic dermatitis but does not reduce allergic responses to inhalant antigens.

Download full-text PDF

Source

Publication Analysis

Top Keywords

atopic dermatitis
12
[cyclosporin atopic
4
dermatitis therapeutic
4
therapeutic allergic
4
allergic reactions
4
reactions dissociated
4
dissociated other]
4
other] fourteen
4
fourteen patients
4
patients severe
4

Similar Publications

Atopic dermatitis (AD) is one of the most common dermatoses. According to current data 2.6 % of the world's population suffer from AD.

View Article and Find Full Text PDF

Atopic dermatitis (AD) is a multifaceted inflammatory skin condition characterized by the involvement of various cell types, such as keratinocytes, macrophages, neutrophils, and mast cells. Research indicates that flavonoids possess anti-inflammatory properties that may be beneficial in the management of AD. However, the investigation of the glycoside forms for anti-AD therapy is limited.

View Article and Find Full Text PDF

Background: Otitis media with effusion (OME) is associated with comorbidities such as allergic rhinitis, gastroesophageal reflux disease, asthma, and more. Many of these comorbidities can be caused by type 2 inflammation (T2I). This study aims to determine the risk of undergoing OME surgery in patients with and without T2I disease.

View Article and Find Full Text PDF

Inflammaging has long been linked to the pathogenesis of various aging-associated disorders, including cardiovascular disease, obesity, type 2 diabetes, and dementia. Yet, the origins of inflammaging remain unclear. Although inflammatory dermatoses such as psoriasis and atopic dermatitis predispose to the development of certain aging-associated disorders, suggesting a pathogenic role of cutaneous inflammation in these disorders, the great majority of aged humans do not have inflammatory dermatoses.

View Article and Find Full Text PDF

Microneedles as transdermal drug delivery system for enhancing skin disease treatment.

Acta Pharm Sin B

December 2024

State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China.

Microneedles (MNs) serve as a revolutionary paradigm in transdermal drug delivery, heralding a viable resolution to the formidable barriers presented by the cutaneous interface. This review examines MNs as an advanced approach to enhancing dermatological pathology management. It explores the complex dermis structure and highlights the limitations of traditional transdermal methods, emphasizing MNs' advantage in bypassing the stratum corneum to deliver drugs directly to the subdermal matrix.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!